Mark J. O’Connor

机构：AstraZeneca (United Kingdom) · ORCID：0000-0003-1823-625X

发表论文 449 篇 · 总被引 22108 次 · h-index 70

代表论文

• Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer (2025 · Cancer Research · 被引 22)
• Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial (2025 · Nature Communications · 被引 20)
• The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study (2025 · British Journal of Cancer · 被引 15)
• ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma (2025 · Journal of Clinical Oncology · 被引 13)
• Use of Direct-to-Biology Strategies for the Discovery of 2′-Deoxynucleoside 5′-Monophosphate N-Glycosidase (DNPH1) PROTACs (2025 · Journal of Medicinal Chemistry · 被引 10)
• Targeting genomic instability in cancer (2026 · Cell · 被引 8)